Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. (Q38108736)

29 August 2017

Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. (English)

1 reference

29 August 2017

0 references

1 reference

Ovidiu Galescu

1

1 reference

29 August 2017

Amrit Bhangoo

series ordinal

2

1 reference

29 August 2017

Svetlana Ten

series ordinal

3

1 reference

29 August 2017

language of work or name

1 reference

1 June 2013

1 reference

Reviews in Endocrine and Metabolic Disorders

29 August 2017

1 reference

29 August 2017

14

1 reference

29 August 2017

2

1 reference

29 August 2017

133-140

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-013-9247-7

29 August 2017

0 references

cites work

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

A comparison of factors associated with prevalent diabetes mellitus among HIV-Infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

HIV infection and the risk of diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Molecular mechanisms for insulin resistance in treated HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Metabolic syndrome and cardiovascular diseases in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Thrombosis and a hypercoagulable state in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Association of C-reactive protein and HIV infection with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Stavudine versus zidovudine and the development of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Lipodystrophy in pediatric HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Endothelial function in HIV-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Untreated HIV infection and large and small artery elasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Progression of coronary artery calcium in men affected by human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Cardiovascular disease in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Effect of darunavir on lipid profile in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Metformin: a cheap and well-tolerated drug that provides benefits for viral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Metformin: the hidden chronicles of a magic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

A review of guidelines for use of growth hormone in pediatric and transition patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-013-9247-7

Fat distribution and metabolic changes in patients with HIV infection

21 January 2018

1 reference

12 December 2020

Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors.

1 reference

12 December 2020

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients

1 reference

12 December 2020

Complications of HIV disease and antiretroviral therapy

1 reference

12 December 2020

Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients

1 reference

12 December 2020

HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction

1 reference

12 December 2020

Soluble adhesion molecules and endothelial cell damage in HIV infected patients

1 reference

12 December 2020

Paediatric European Network for Treatment of AIDS response to 2010 revision of World Health Organization recommendations on 'Antiretroviral therapy for HIV infection in infants and children'

1 reference

12 December 2020

[Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients].

1 reference

12 December 2020

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

1 reference

12 December 2020

Plasma hypercoagulability is correlated to plasma HIV load

1 reference

12 December 2020

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

1 reference

12 December 2020

Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study

1 reference

12 December 2020

Regulation of adiponectin in adipocytes upon exposure to HIV-1

1 reference

12 December 2020

Coronary artery disease and HIV; getting to the HAART of the matter

1 reference

12 December 2020

Endothelial cell dysfunction in HIV infection

1 reference

12 December 2020

Metabolic abnormalities and use of HIV-1 protease inhibitors

1 reference

12 December 2020

10.1007/S11154-013-9247-7

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference